The call began with Tracy McCarthy addressing the audience, setting the stage for a discussion on Biogen's Q1 2026 financial performance. Forward-looking statements were highlighted, emphasizing the company's business prospects and potential future products. Non-GAAP financial measures were explained, noting their supplementary role to GAAP-compliant measures. Management, led by CEO, CFO, CCO, and CRO, provided insights into product programs, regulatory actions, market dynamics, and competitive developments, concluding with a Q&A session.

Biomarin accelerates 2026 revenue growth by 20% with Amicus acquisition, integrating innovative therapies for Fabry and Pompe diseases, and enhancing portfolio with Enzyme and Scalable Conditions divisions. Strong PKU community interest post adolescent label expansion and robust Box Sogo demand highlight focused investments and patient-centric strategies.

The dialogue highlights a pivotal year for Bimar, focusing on the integration of Abas, regulatory milestones, and the addition of Galop and Probability Off to the portfolio, aiming to expand global patient reach and create value for stakeholders.

Q1 2026 revenues increased year-over-year to $766 million, impacted by order timing and lower royalties. Full-year guidance raised to $3.825B-$3.925B, including Amicus contributions, with earnings per share updated to $4.85-$5.05. Amicus acquisition expected to be accretive post-2026, with second-half revenue and profitability emphasized.

The company reports robust year-over-year growth in enzyme therapies, driven by strong patient demand and successful product launches. Key achievements include expanding the patient base for Palin Z in adolescents post FDA approval, observing a significant increase in new patient starts for rosdoagh, and making strides in early diagnosis and treatment for achondroplasia. The focus remains on geographic expansion and maximizing the potential of existing products, with promising developments in the pipeline, including potential approval for hypochondroplasia in 2027.

A detailed evidence package for Vaso Go showcases sustained efficacy and safety across pediatric age groups, with long-term follow-up data from ongoing studies. The therapy's positive impact on height, quality of life, and bone formation is emphasized, supported by a robust safety database. This comprehensive data supports a full approval submission to the FDA, aiming to demonstrate Vaso Go's long-term value in pediatric care.

Upcoming pivotal data readouts for hypochondroplasia and en PD 1 deficiency, alongside progress in bmn 333 and bmn 305 1 programs, highlight advancements in targeted therapies for rare diseases, with gratitude to patients and caregivers for their contributions.

Discussed pediatric endocanna's positive impact on bone mineral content and hypochondroplasia, aligning with healthy bone growth seen in achondroplasia, reinforcing expectations for phase 3 study outcomes, with no anticipated safety concerns.

The dialogue highlights the potential for increased switch rates in the Amicus market through enhanced diagnosis efforts and patient progression understanding. Key strategies include leveraging Biomarin's capabilities to diagnose more amenable patients, initiating new therapies for those aware of their disease progression, and generating evidence to support therapy switches, aiming for significant growth over the next few years.

Despite competitor entry, Block Sogo maintains strong demand and increasing enrollments. Focus on the 0-2 population shows promising results, with a 10% reduction in time from diagnosis to treatment. Efforts are ongoing to ensure continued positive experiences for patients already on treatment.

Following the Amicus acquisition, Biomarin previews Q2 with updates on revenue synergies, long-term growth potential, and reaffirms calendar 26 accretion. The company outlines plans for integrating Amicus, emphasizing global capabilities and commercial opportunities, while hinting at higher-than-expected peak revenue potential for key medicines. A detailed Q2 update will include metrics on peak revenue, synergy strategies, and long-term profitability, reflecting a strong start to the integration process.

A discussion on upcoming data from the hypochondroplasia study, emphasizing growth improvement and safety. Preparations include accelerating diagnosis, genetic testing, and reclassifying variants, aiming for earlier patient identification and readiness for therapy. Notable progress includes a 90% increase in identified patients and a 70% reduction in diagnosis age.

Discussed the $500 million guidance increase for Bitcoin, highlighting it as realistic and neither conservative nor aggressive. The integration post-closing shows strong initial performance, with projected healthy growth rates, indicating optimism for future revenue contributions.

Discussion covers hypodermic adoption for achondroplasia in Asian markets, highlighting similarities and differences. Bridges gap between patient growth and revenue, considering larger orders in Q4's impact.

The dialogue focuses on strategies to increase disease awareness and the urgency of treatment for hypochondroplasia, aiming to accelerate the adoption curve of therapies. It also discusses the impact of order timing on reported revenues, highlighting the significance of patient demand growth. Additionally, there's an update on the ITC hearing and anticipation of data release from a phase 2/3 trial in 2027, underscoring the importance of intellectual property protection and enforcement.

The dialogue discusses the strategic decision to pursue a superiority trial for BMN 333, a long-acting CNP analog, in children with chondroplasty, emphasizing the benefits of higher efficacy, active control with Voxzogo, and rapid patient recruitment over a non-inferiority design. The trial aims to demonstrate superiority in annualized growth velocity and health measures, leveraging Bayesian analysis for dose selection and phase 3 progression.

Discussion focuses on Biomarin's cautious stance regarding the combination of growth hormone with CMP, noting early studies suggest additional growth potential but requiring more data on safety and long-term efficacy. The role of CCC3 in this evolving landscape is explored, emphasizing the need for further evaluation before paradigm shifts.

Discussion focuses on aligning expectations for enzyme therapies growth, emphasizing full-year comparison over quarterly fluctuations, with guidance increase attributed to strong first-half performance and annual cycle analysis.

Bank of America shares strategies post Amicus acquisition, focusing on global market expansion for patient therapies. Highlights include expanding commercial reach, enhancing patient service globally, and anticipating continued momentum from recent product launches. The bank emphasizes the importance of early treatment initiation and is focused on translating current momentum into broader patient impact and value creation. Upcoming catalysts in the pipeline are also noted for future growth.